First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $40M — +2905% growth in a single year.
What Moves the Stock
1Phase 2/3 clinical trial data readouts for deucrictibant and PHA122 - efficacy endpoints (attack reduction, time to relief), safety profile versus placebo and active comparators
2FDA and EMA regulatory milestone announcements - IND/NDA filings, Breakthrough Therapy designations, PDUFA date assignments, approval decisions
3Partnership or licensing deal announcements with major pharma for commercialization rights, particularly ex-US territories
4Cash runway updates and financing events - equity raises, debt facilities, or non-dilutive funding that extend operational runway beyond 12-18 months
5Competitive developments in HAE market - approvals or setbacks for BioCryst (Orladeyo), Takeda, Ionis, or other oral HAE programs
6No current revenue - pre-commercial stage
7Future revenue expected from deucrictibant (on-demand HAE treatment) upon approval
8Future revenue expected from PHA122 (prophylactic HAE treatment) upon approval
growth - Pharvaris attracts speculative growth investors and biotech specialists willing to accept binary clinical/regulatory risk…
Rising interest rates negatively impact Pharvaris through two channels: (1) Higher discount rates compress NPV of future cash flows…
Watch on earnings: Phase 3 trial enrollment completion dates and interim analysis timing for deucrictibant and PHA122, Monthly cash burn rate and quarterly cash balance updates to assess runway, FDA Breakthrough Therapy or Fast Track designation status for accelerated approval pathways.
One Sentence Summary:
Pharvaris: the story is balanced — phase 2/3 clinical trial data readouts for deucrictibant and pha122 - efficacy endpoints (attack reduction, time to relief).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.